Altretamine |
Hexalen; Hexamethylmelamine |
Article: Altretamine
![]() | |
| Altretamine | |
| Systematic (IUPAC) name | |
| N2,N2,N4,N4,N6,N6-hexamethyl-1,3,5-triazine-2,4,6-triamine | |
| Identifiers | |
| CAS number | 645-05-6 |
| ATC code | L01XX03 |
| PubChem | 2123 |
| DrugBank | APRD00652 |
| Chemical data | |
| Formula | C9H18N6 |
| Mol. weight | 210.28 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 94% |
| Metabolism | ? |
| Half life | 4.7-10.2 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. | ? |
| Legal status | |
| Routes | ? |
Altretamine (also hexalen) is a drug that is used to treat ovarian cancer. The precise mechanism by which altretamine exerts its anti-cancer effect is unknown. It was approved by the FDA in 1990.
Resources
- Altretamine (Drug Digest)
- Hexalen (Drug Digest)

Not Signed In - 

